Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Реалии и перспективы применения прокинетика акотиамида в гастроэнтерологии
Маев И.В., Андреев Д.Н., Заборовский А.В., Лобанова Е.Г. Реалии и перспективы применения прокинетика акотиамида в гастроэнтерологии. Терапевтический архив. 2023;95(8):716–721.
DOI: 10.26442/00403660.2023.08.202396
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/00403660.2023.08.202396
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Maev IV, Andreev DN, Zaborovsky AV, Lobanova EG. Current status and prospects of using the prokinetic acotiamide in gastroenterology: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(8):716–721.
DOI: 10.26442/00403660.2023.08.202396
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Акотиамид является прокинетиком принципиально нового механизма действия – антагонист мускариновых М1- и М2-рецепторов, а также ингибитор ацетилхолинэстеразы. Блокада М1- и М2-рецепторов на пресинаптической мембране нивелирует тормозное влияние по механизму обратной отрицательной связи на синтез ацетилхолина, тогда как ингибирование ацетилхолинэстеразы в синаптической щели снижает распад данного нейротрансмиттера, который представляет собой основной медиатор тонуса мышечных компонентов желудочно-кишечного тракта, увеличивая его моторную активность. В настоящее время клиническая эффективность молекулы акотиамида на популяции пациентов с функциональной диспепсией показана более чем в 10 клинических исследованиях из разных регионов мира, демонстрирующих регресс симптоматики заболевания на фоне применения данного прокинетика и улучшение качества жизни пациентов. Помимо этого комбинация акотиамида с ингибиторами протонной помпы позволяет оптимизировать тактику ведения пациентов с симптомами гастроэзофагеальной рефлюксной болезни.
Ключевые слова: прокинетики, акотиамид, функциональная диспепсия, гастроэзофагеальная рефлюксная болезнь
Ключевые слова: прокинетики, акотиамид, функциональная диспепсия, гастроэзофагеальная рефлюксная болезнь
________________________________________________
Acotiamide is a prokinetic with a novel mechanism of action – an antagonist of muscarinic M1 and M2 receptors and an acetylcholinesterase inhibitor. Acetylcholine is the central mediator of the tone of the muscular components of the gastrointestinal tract, increasing its motor activity. Blockade of presynaptic M1 and M2 receptors neutralizes the inhibitory effect of the feedback mechanism on the acetylcholine synthesis, while inhibition of acetylcholinesterase in the synaptic cleft reduces the acetylcholine degradation. Currently, the clinical efficacy of acotiamide in the population of patients with functional dyspepsia is demonstrated in more than 10 clinical studies in different regions of the world, demonstrating a reduction of the symptoms of the disease during treatment with this agent and an improvement in the quality of life of patients. In addition, the combination of acotiamide with proton pump inhibitors optimizes the management of patients with gastroesophageal reflux disease.
Keywords: prokinetics, acotiamide, functional dyspepsia, gastroesophageal reflux disease
Полный текст
Список литературы
1. Маев И.В., Бусарова Г.А., Андреев Д.Н. Болезни пищевода. М.: ГЭОТАР-Медиа, 2019 [Maev IV, Busarova GA, Andreev DN. Bolezni pishchevoda. Moscow: GEOTAR-Media, 2019 (in Russian)].
2. Ахмедов В.А. Моторные нарушения пищеварительного тракта: терапия прокинетиками. РМЖ. Медицинское обозрение. 2022;6(5):252-7 [Akhmedov VA. Gastrointestinal motor disorders: treatment with prokinetics. Russian Medical Inquiry. 2022;6(5):252-8 (in Russian)]. DOI:10.32364/2587-6821-2022-6-5-252-258
3. Goodman LS, Gilman A, Brunton LL, et al. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011.
4. Galligan J. Pharmacology of synaptic transmission in the enteric nervous system. Curr Opin Pharmacol. 2002;2(6):623-9. DOI:10.1016/s1471-4892(02)00212-6
5. Маев И.В., Дичева Д.Т., Андреев Д.Н., и др. Терапевтическая роль прокинетических препаратов в лечении гастроэзофагеальной рефлюксной болезни. Медицинский совет. 2014;(4):66-70 [Mayev IV, Dicheva DT, Andreyev DN, et al. Therapeutic role of prokinetic drugs in the treatment of gastroesophageal reflux disease. Meditsinskiy sovet = Medical Council. 2014;(4):66-71 (in Russian)]. DOI:10.21518/2079-701X-2014-4-66-71
6. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol. 2008;8(6):690-6. DOI:10.1016/j.coph.2008.09.009
7. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Фармакотерапия заболеваний верхних отделов ЖКТ. М.: ООО «Группа Ремедиум», 2021 [Maev IV, Andreev DN, Kucheriavyi IuA. Farmakoterapiia zabolevanii verkhnikh otdelov ZhKT. Moscow: OOO «Gruppa Remedium», 2021 (in Russian)].
8. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(4):CD001960. DOI:10.1002/14651858.CD001960.pub3
9. Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol. 2019;114(2):233-43.
10. Xi L, Zhu J, Zhang H, et al. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis. Esophagus. 2021;18(1):144-51. DOI:10.1007/s10388-020-00753-6
11. Doi Y, Murasaki O, Kaibara M, et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1-3):31-5. DOI:10.1016/j.ejphar.2004.10.003
12. Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther. 2000;294(1):33-7.
13. Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791-800. DOI:10.1124/jpet.110.174847
14. Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol. 2011;666(1‑3):218‑25. DOI:10.1016/j.ejphar.2011.05.049
15. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Report on the deliberation results (Acofide tablets 100 mg). Available at:
https://www.pmda.go.jp/files/000153467.pdf. Accessed: 13.06.2023.
16. Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821-8.
DOI:10.1136/gutjnl-2011-301454
17. Matsunaga Y, Kawachi M, Hori Y, et al. Influence of acotiamide hydrochloride hydrate, a drug for the treatment of functional dyspepsia, on the antisecretory effect of acid suppressants in rats. Japanese Pharmacology and Therapeutics. 2013;41(7):655-60.
18. Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil. 2012;24(6):566‑e256.
19. Yamawaki H, Futagami S, Kawagoe T, et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037-47. DOI:10.1111/nmo.12805
20. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86(10):4753-8. DOI:10.1210/jcem.86.10.7885
21. Yagi T, Asakawa A, Ueda H, et al. The role of ghrelin in patients with functional dyspepsia and its potential clinical relevance (Review). Int J Mol Med. 2013;32(3):523-31. DOI:10.3892/ijmm.2013.1418
22. Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;79(2):65-72. DOI:10.1159/000205740
23. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Функциональная диспепсия: эпидемиология, классификация, этиопатогенез, диагностика и лечение: научное досье. М.: ООО «СТ-Принт», 2015 [Maev IV, Kucheriavyi IuA, Andreev DN. Funktsional'naia dispepsiia: epidemiologiia, klassifikatsiia, etiopatogenez, diagnostika i lechenie: nauchnoe dos'e. Moscow: OOO «ST-Print», 2015 (in Russian)].
24. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-92.
25. Маев И.В., Дичева Д.Т., Щегланова М.П., и др. Функциональная диспепсия в свете Римских критериев IV пересмотра (2016 г.). Гастроэнтерология. Приложение к журналу Consilium Medicum. 2016;2:5-10 [Maev IV, Dicheva DT, Shcheglanova MP, et al. Functional dyspepsia in the context of the 2016 Rome IV updates. Consilium Medicum. Gastroenterology (Suppl.). 2016;2:5-10 (in Russian)].
26. Маев И.В., Андреев Д.Н., Дичева Д.Т., и др. Функциональная диспепсия: современное состояние проблемы. Медицинский вестник МВД. 2013;4:38-45 [Maev IV, Andreev DN, Dicheva DT, et al. Funktsional'naia dispepsiia: sovremennoe sostoianie problemy. Meditsinskii vestnik MVD. 2013;4:38-45 (in Russian)].
27. Ford AC, Mahadeva S, Carbone MF, et al. Functional dyspepsia. Lancet. 2020;396(10263):1689-702. DOI:10.1016/S0140-6736(20)30469-4
28. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. DOI:10.1053/j.gastro.2020.04.014
29. Xiao G, Xie X, Fan J, et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis. Scientific World Journal. 2014;2014:541950. DOI:10.1155/2014/541950
30. Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618-e173. DOI:10.1111/j.1365-2982.2009.01449.x
31. Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261-8. DOI:10.1159/000332404
32. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540-5,e250-1. DOI:10.1111/j.1365-2982.2012.01897.x
33. Shinozaki S, Osawa H, Sakamoto H, et al. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63(3-4):230-5. DOI:10.2152/jmi.63.230
34. Muta K, Ihara E, Fukaura K, et al. Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders: A Pilot Study. Digestion. 2016;94(1):9-16. DOI:10.1159/000447010
35. Shinozaki S, Osawa H, Sakamoto H, et al. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis. 2017;26(4):345-50. DOI:10.15403/jgld.2014.1121.264.ski
36. Tack J, Pokrotnieks J, Urbonas G, et al. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome) – results from the European phase 3 open-label safety trial. Neurogastroenterol Motil. 2018;30(6):e13284. DOI:10.1111/nmo.13284
37. Mizukami K, Katsuta M, Okamoto K, et al. Influence of acotiamide on 13C-urea breath test for Helicobacter pylori diagnosis. J Clin Biochem Nutr. 2020;67(3):332-7. DOI:10.3164/jcbn.20-17
38. Бакулин И.Г., Хлынов И.Б., Саблин О.А., и др. Клиническая эффективность применения акотиамида у пациентов с функциональной диспепсией: результаты многоцентрового исследования. Медицинский совет. 2023;(13):108-15 [Bakulin IG, Khlynov IB, Sablin OA, et al. Clinical efficacy of acotiamide in patients with functional dyspepsia: results of a multicenter study. Meditsinskiy sovet = Medical Council. 2023;(13):108-15 (in Russian)]. DOI:10.21518/ms2023-253
39. Miwa H, Nagahara A, Asakawa A, et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47‑61.
DOI:10.1007/s00535-021-01843-7
40. Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697-723.
DOI:10.1136/gutjnl-2022-327737
41. Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70‑97 (in Russian)]. DOI:10.22416/1382-4376-2020-30-4-70-97
42. Маев И.В., Юренев Г.Л., Вьючнова Е.С., и др. Гастроэзофагеальная рефлюксная болезнь. М.: ГЭОТАР-Медиа, 2019 [Maev IV, Iurenev GL, V'iuchnova ES, et al. Gastroezofageal'naia refliuksnaia bolezn'. Moscow: GEOTAR-Media, 2019 (in Russian)].
43. Maleki I, Masoudzadeh A, Khalilian A, Daheshpour E. Quality of life in patients with gastroesophageal reflux disease in an Iranian population. Gastroenterol Hepatol Bed Bench. 2013;6(2):96-100.
44. Gorczyca R, Pardak P, Pękala A, Filip R. Impact of gastroesophageal reflux disease on the quality of life of Polish patients. World J Clin Cases. 2019;7(12):1421-9. DOI:10.12998/wjcc.v7.i12.1421
45. Nirwan JS, Hasan SS, Babar ZU, et al. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep. 2020;10(1):5814. DOI:10.1038/s41598-020-62795-1
46. Бордин Д.С., Абдулхаков Р.А., Осипенко М.Ф., и др. Многоцентровое исследование распространенности симптомов гастроэзофагеальной рефлюксной болезни у пациентов поликлиник в России. Терапевтический архив. 2022;94(1):48-56 [Bordin DS, Abdulkhakov RА, Osipenko MF, et al. Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(1):48-56 (in Russian)]. DOI:10.26442/00403660.2022.01.201322
47. Маев И.В., Дичева Д.Т., Андреев Д.Н. Возможности применения домперидона в комплексной терапии гастроэзофагеальной рефлюксной болезни. Медицинский совет. 2012;(2):56-60 [Maev IV, Dicheva DT, Andreev DN. Vozmozhnosti primeneniia domperidona v kompleksnoi terapii gastroezofageal'noi refliuksnoi bolezni. Meditsinskiy sovet = Medical Council. 2012;(2):56-60 (in Russian)].
48. Андреев Д.Н., Кучерявый Ю.А. Перспективы лечения гастроэзофагеальной рефлюксной болезни. Consilium Medicum. Гастроэнтерология. 2013;2:9-14 [Andreev DN, Kucheriavyi IuA. Perspektivy lecheniia gastroezofageal'noi refliuksnoi bolezni. Consilium Medicum. Gastroenterologiia. 2013;2:9-14 (in Russian)].
49. Кучерявый Ю.А., Андреев Д.Н. Перспективы лечения больных с кислотозависимыми заболеваниями. Клин. перспективы гастроэнтерол., гепатол. 2014;2:15-24 [Kucheriavyi IuA, Andreev DN. Perspektivy lecheniia bol'nykh s kislotozavisimymi zabolevaniiami. Klin. perspektivy gastroenterol., gepatol. 2014;2:15-24 (in Russian)].
50. Yamashita H, Okada A, Naora K, et al. Adding acotiamide to gastric acid inhibitors is effective for treating refractory symptoms in patients with non-erosive reflux disease. Dig Dis Sci. 2019;64(3):823-31. DOI:10.1007/s10620-018-5377-9
2. Ахмедов В.А. Моторные нарушения пищеварительного тракта: терапия прокинетиками. РМЖ. Медицинское обозрение. 2022;6(5):252-7 [Akhmedov VA. Gastrointestinal motor disorders: treatment with prokinetics. Russian Medical Inquiry. 2022;6(5):252-8 (in Russian)]. DOI:10.32364/2587-6821-2022-6-5-252-258
3. Goodman LS, Gilman A, Brunton LL, et al. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011.
4. Galligan J. Pharmacology of synaptic transmission in the enteric nervous system. Curr Opin Pharmacol. 2002;2(6):623-9. DOI:10.1016/s1471-4892(02)00212-6
5. Маев И.В., Дичева Д.Т., Андреев Д.Н., и др. Терапевтическая роль прокинетических препаратов в лечении гастроэзофагеальной рефлюксной болезни. Медицинский совет. 2014;(4):66-70 [Mayev IV, Dicheva DT, Andreyev DN, et al. Therapeutic role of prokinetic drugs in the treatment of gastroesophageal reflux disease. Meditsinskiy sovet = Medical Council. 2014;(4):66-71 (in Russian)]. DOI:10.21518/2079-701X-2014-4-66-71
6. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol. 2008;8(6):690-6. DOI:10.1016/j.coph.2008.09.009
7. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Фармакотерапия заболеваний верхних отделов ЖКТ. М.: ООО «Группа Ремедиум», 2021 [Maev IV, Andreev DN, Kucheriavyi IuA. Farmakoterapiia zabolevanii verkhnikh otdelov ZhKT. Moscow: OOO «Gruppa Remedium», 2021 (in Russian)].
8. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(4):CD001960. DOI:10.1002/14651858.CD001960.pub3
9. Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol. 2019;114(2):233-43.
10. Xi L, Zhu J, Zhang H, et al. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis. Esophagus. 2021;18(1):144-51. DOI:10.1007/s10388-020-00753-6
11. Doi Y, Murasaki O, Kaibara M, et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1-3):31-5. DOI:10.1016/j.ejphar.2004.10.003
12. Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther. 2000;294(1):33-7.
13. Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791-800. DOI:10.1124/jpet.110.174847
14. Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol. 2011;666(1‑3):218‑25. DOI:10.1016/j.ejphar.2011.05.049
15. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Report on the deliberation results (Acofide tablets 100 mg). Available at:
https://www.pmda.go.jp/files/000153467.pdf. Accessed: 13.06.2023.
16. Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821-8.
DOI:10.1136/gutjnl-2011-301454
17. Matsunaga Y, Kawachi M, Hori Y, et al. Influence of acotiamide hydrochloride hydrate, a drug for the treatment of functional dyspepsia, on the antisecretory effect of acid suppressants in rats. Japanese Pharmacology and Therapeutics. 2013;41(7):655-60.
18. Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil. 2012;24(6):566‑e256.
19. Yamawaki H, Futagami S, Kawagoe T, et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037-47. DOI:10.1111/nmo.12805
20. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86(10):4753-8. DOI:10.1210/jcem.86.10.7885
21. Yagi T, Asakawa A, Ueda H, et al. The role of ghrelin in patients with functional dyspepsia and its potential clinical relevance (Review). Int J Mol Med. 2013;32(3):523-31. DOI:10.3892/ijmm.2013.1418
22. Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;79(2):65-72. DOI:10.1159/000205740
23. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Функциональная диспепсия: эпидемиология, классификация, этиопатогенез, диагностика и лечение: научное досье. М.: ООО «СТ-Принт», 2015 [Maev IV, Kucheriavyi IuA, Andreev DN. Funktsional'naia dispepsiia: epidemiologiia, klassifikatsiia, etiopatogenez, diagnostika i lechenie: nauchnoe dos'e. Moscow: OOO «ST-Print», 2015 (in Russian)].
24. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-92.
25. Маев И.В., Дичева Д.Т., Щегланова М.П., и др. Функциональная диспепсия в свете Римских критериев IV пересмотра (2016 г.). Гастроэнтерология. Приложение к журналу Consilium Medicum. 2016;2:5-10 [Maev IV, Dicheva DT, Shcheglanova MP, et al. Functional dyspepsia in the context of the 2016 Rome IV updates. Consilium Medicum. Gastroenterology (Suppl.). 2016;2:5-10 (in Russian)].
26. Маев И.В., Андреев Д.Н., Дичева Д.Т., и др. Функциональная диспепсия: современное состояние проблемы. Медицинский вестник МВД. 2013;4:38-45 [Maev IV, Andreev DN, Dicheva DT, et al. Funktsional'naia dispepsiia: sovremennoe sostoianie problemy. Meditsinskii vestnik MVD. 2013;4:38-45 (in Russian)].
27. Ford AC, Mahadeva S, Carbone MF, et al. Functional dyspepsia. Lancet. 2020;396(10263):1689-702. DOI:10.1016/S0140-6736(20)30469-4
28. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. DOI:10.1053/j.gastro.2020.04.014
29. Xiao G, Xie X, Fan J, et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis. Scientific World Journal. 2014;2014:541950. DOI:10.1155/2014/541950
30. Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618-e173. DOI:10.1111/j.1365-2982.2009.01449.x
31. Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261-8. DOI:10.1159/000332404
32. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540-5,e250-1. DOI:10.1111/j.1365-2982.2012.01897.x
33. Shinozaki S, Osawa H, Sakamoto H, et al. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63(3-4):230-5. DOI:10.2152/jmi.63.230
34. Muta K, Ihara E, Fukaura K, et al. Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders: A Pilot Study. Digestion. 2016;94(1):9-16. DOI:10.1159/000447010
35. Shinozaki S, Osawa H, Sakamoto H, et al. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis. 2017;26(4):345-50. DOI:10.15403/jgld.2014.1121.264.ski
36. Tack J, Pokrotnieks J, Urbonas G, et al. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome) – results from the European phase 3 open-label safety trial. Neurogastroenterol Motil. 2018;30(6):e13284. DOI:10.1111/nmo.13284
37. Mizukami K, Katsuta M, Okamoto K, et al. Influence of acotiamide on 13C-urea breath test for Helicobacter pylori diagnosis. J Clin Biochem Nutr. 2020;67(3):332-7. DOI:10.3164/jcbn.20-17
38. Бакулин И.Г., Хлынов И.Б., Саблин О.А., и др. Клиническая эффективность применения акотиамида у пациентов с функциональной диспепсией: результаты многоцентрового исследования. Медицинский совет. 2023;(13):108-15 [Bakulin IG, Khlynov IB, Sablin OA, et al. Clinical efficacy of acotiamide in patients with functional dyspepsia: results of a multicenter study. Meditsinskiy sovet = Medical Council. 2023;(13):108-15 (in Russian)]. DOI:10.21518/ms2023-253
39. Miwa H, Nagahara A, Asakawa A, et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47‑61.
DOI:10.1007/s00535-021-01843-7
40. Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697-723.
DOI:10.1136/gutjnl-2022-327737
41. Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70‑97 (in Russian)]. DOI:10.22416/1382-4376-2020-30-4-70-97
42. Маев И.В., Юренев Г.Л., Вьючнова Е.С., и др. Гастроэзофагеальная рефлюксная болезнь. М.: ГЭОТАР-Медиа, 2019 [Maev IV, Iurenev GL, V'iuchnova ES, et al. Gastroezofageal'naia refliuksnaia bolezn'. Moscow: GEOTAR-Media, 2019 (in Russian)].
43. Maleki I, Masoudzadeh A, Khalilian A, Daheshpour E. Quality of life in patients with gastroesophageal reflux disease in an Iranian population. Gastroenterol Hepatol Bed Bench. 2013;6(2):96-100.
44. Gorczyca R, Pardak P, Pękala A, Filip R. Impact of gastroesophageal reflux disease on the quality of life of Polish patients. World J Clin Cases. 2019;7(12):1421-9. DOI:10.12998/wjcc.v7.i12.1421
45. Nirwan JS, Hasan SS, Babar ZU, et al. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep. 2020;10(1):5814. DOI:10.1038/s41598-020-62795-1
46. Бордин Д.С., Абдулхаков Р.А., Осипенко М.Ф., и др. Многоцентровое исследование распространенности симптомов гастроэзофагеальной рефлюксной болезни у пациентов поликлиник в России. Терапевтический архив. 2022;94(1):48-56 [Bordin DS, Abdulkhakov RА, Osipenko MF, et al. Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(1):48-56 (in Russian)]. DOI:10.26442/00403660.2022.01.201322
47. Маев И.В., Дичева Д.Т., Андреев Д.Н. Возможности применения домперидона в комплексной терапии гастроэзофагеальной рефлюксной болезни. Медицинский совет. 2012;(2):56-60 [Maev IV, Dicheva DT, Andreev DN. Vozmozhnosti primeneniia domperidona v kompleksnoi terapii gastroezofageal'noi refliuksnoi bolezni. Meditsinskiy sovet = Medical Council. 2012;(2):56-60 (in Russian)].
48. Андреев Д.Н., Кучерявый Ю.А. Перспективы лечения гастроэзофагеальной рефлюксной болезни. Consilium Medicum. Гастроэнтерология. 2013;2:9-14 [Andreev DN, Kucheriavyi IuA. Perspektivy lecheniia gastroezofageal'noi refliuksnoi bolezni. Consilium Medicum. Gastroenterologiia. 2013;2:9-14 (in Russian)].
49. Кучерявый Ю.А., Андреев Д.Н. Перспективы лечения больных с кислотозависимыми заболеваниями. Клин. перспективы гастроэнтерол., гепатол. 2014;2:15-24 [Kucheriavyi IuA, Andreev DN. Perspektivy lecheniia bol'nykh s kislotozavisimymi zabolevaniiami. Klin. perspektivy gastroenterol., gepatol. 2014;2:15-24 (in Russian)].
50. Yamashita H, Okada A, Naora K, et al. Adding acotiamide to gastric acid inhibitors is effective for treating refractory symptoms in patients with non-erosive reflux disease. Dig Dis Sci. 2019;64(3):823-31. DOI:10.1007/s10620-018-5377-9
________________________________________________
1. Maev IV, Busarova GA, Andreev DN. Bolezni pishchevoda. Moscow: GEOTAR-Media, 2019 (in Russian).
2. Akhmedov VA. Gastrointestinal motor disorders: treatment with prokinetics. Russian Medical Inquiry. 2022;6(5):252-8 (in Russian). DOI:10.32364/2587-6821-2022-6-5-252-258
3. Goodman LS, Gilman A, Brunton LL, et al. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011.
4. Galligan J. Pharmacology of synaptic transmission in the enteric nervous system. Curr Opin Pharmacol. 2002;2(6):623-9. DOI:10.1016/s1471-4892(02)00212-6
5. Mayev IV, Dicheva DT, Andreyev DN, et al. Therapeutic role of prokinetic drugs in the treatment of gastroesophageal reflux disease. Meditsinskiy sovet = Medical Council.
2014;(4):66-71 (in Russian). DOI:10.21518/2079-701X-2014-4-66-71
6. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol. 2008;8(6):690-6. DOI:10.1016/j.coph.2008.09.009
7. Maev IV, Andreev DN, Kucheriavyi IuA. Farmakoterapiia zabolevanii verkhnikh otdelov ZhKT. Moscow: OOO «Gruppa Remedium», 2021 (in Russian).
8. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(4):CD001960. DOI:10.1002/14651858.CD001960.pub3
9. Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol. 2019;114(2):233-43.
10. Xi L, Zhu J, Zhang H, et al. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis. Esophagus. 2021;18(1):144-51. DOI:10.1007/s10388-020-00753-6
11. Doi Y, Murasaki O, Kaibara M, et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1-3):31-5. DOI:10.1016/j.ejphar.2004.10.003
12. Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther. 2000;294(1):33-7.
13. Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791-800. DOI:10.1124/jpet.110.174847
14. Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol. 2011;666(1‑3):218‑25. DOI:10.1016/j.ejphar.2011.05.049
15. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Report on the deliberation results (Acofide tablets 100 mg). Available at:
https://www.pmda.go.jp/files/000153467.pdf. Accessed: 13.06.2023.
16. Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821-8.
DOI:10.1136/gutjnl-2011-301454
17. Matsunaga Y, Kawachi M, Hori Y, et al. Influence of acotiamide hydrochloride hydrate, a drug for the treatment of functional dyspepsia, on the antisecretory effect of acid suppressants in rats. Japanese Pharmacology and Therapeutics. 2013;41(7):655-60.
18. Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil. 2012;24(6):566‑e256.
19. Yamawaki H, Futagami S, Kawagoe T, et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037-47. DOI:10.1111/nmo.12805
20. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86(10):4753-8. DOI:10.1210/jcem.86.10.7885
21. Yagi T, Asakawa A, Ueda H, et al. The role of ghrelin in patients with functional dyspepsia and its potential clinical relevance (Review). Int J Mol Med. 2013;32(3):523-31. DOI:10.3892/ijmm.2013.1418
22. Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;79(2):65-72. DOI:10.1159/000205740
23. Maev IV, Kucheriavyi IuA, Andreev DN. Funktsional'naia dispepsiia: epidemiologiia, klassifikatsiia, etiopatogenez, diagnostika i lechenie: nauchnoe dos'e. Moscow: OOO «ST-Print», 2015 (in Russian).
24. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-92.
25. Maev IV, Dicheva DT, Shcheglanova MP, et al. Functional dyspepsia in the context of the 2016 Rome IV updates. Consilium Medicum. Gastroenterology (Suppl.). 2016;2:5-10 (in Russian).
26. Maev IV, Andreev DN, Dicheva DT, et al. Funktsional'naia dispepsiia: sovremennoe sostoianie problemy. Meditsinskii vestnik MVD. 2013;4:38-45 (in Russian).
27. Ford AC, Mahadeva S, Carbone MF, et al. Functional dyspepsia. Lancet. 2020;396(10263):1689-702. DOI:10.1016/S0140-6736(20)30469-4
28. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. DOI:10.1053/j.gastro.2020.04.014
29. Xiao G, Xie X, Fan J, et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis. Scientific World Journal. 2014;2014:541950. DOI:10.1155/2014/541950
30. Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618-e173. DOI:10.1111/j.1365-2982.2009.01449.x
31. Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261-8. DOI:10.1159/000332404
32. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540-5,e250-1. DOI:10.1111/j.1365-2982.2012.01897.x
33. Shinozaki S, Osawa H, Sakamoto H, et al. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63(3-4):230-5. DOI:10.2152/jmi.63.230
34. Muta K, Ihara E, Fukaura K, et al. Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders: A Pilot Study. Digestion. 2016;94(1):9-16. DOI:10.1159/000447010
35. Shinozaki S, Osawa H, Sakamoto H, et al. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis. 2017;26(4):345-50. DOI:10.15403/jgld.2014.1121.264.ski
36. Tack J, Pokrotnieks J, Urbonas G, et al. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome) – results from the European phase 3 open-label safety trial. Neurogastroenterol Motil. 2018;30(6):e13284. DOI:10.1111/nmo.13284
37. Mizukami K, Katsuta M, Okamoto K, et al. Influence of acotiamide on 13C-urea breath test for Helicobacter pylori diagnosis. J Clin Biochem Nutr. 2020;67(3):332-7. DOI:10.3164/jcbn.20-17
38. Bakulin IG, Khlynov IB, Sablin OA, et al. Clinical efficacy of acotiamide in patients with functional dyspepsia: results of a multicenter study. Meditsinskiy sovet = Medical Council. 2023;(13):108-15 (in Russian). DOI:10.21518/ms2023-253
39. Miwa H, Nagahara A, Asakawa A, et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47‑61.
DOI:10.1007/s00535-021-01843-7
40. Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697-723.
DOI:10.1136/gutjnl-2022-327737
41. Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70‑97 (in Russian). DOI:10.22416/1382-4376-2020-30-4-70-97
42. Maev IV, Iurenev GL, V'iuchnova ES, et al. Gastroezofageal'naia refliuksnaia bolezn'. Moscow: GEOTAR-Media, 2019 (in Russian).
43. Maleki I, Masoudzadeh A, Khalilian A, Daheshpour E. Quality of life in patients with gastroesophageal reflux disease in an Iranian population. Gastroenterol Hepatol Bed Bench. 2013;6(2):96-100.
44. Gorczyca R, Pardak P, Pękala A, Filip R. Impact of gastroesophageal reflux disease on the quality of life of Polish patients. World J Clin Cases. 2019;7(12):1421-9. DOI:10.12998/wjcc.v7.i12.1421
45. Nirwan JS, Hasan SS, Babar ZU, et al. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep. 2020;10(1):5814. DOI:10.1038/s41598-020-62795-1
46. Bordin DS, Abdulkhakov RА, Osipenko MF, et al. Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(1):48-56 (in Russian). DOI:10.26442/00403660.2022.01.201322
47. Maev IV, Dicheva DT, Andreev DN. Vozmozhnosti primeneniia domperidona v kompleksnoi terapii gastroezofageal'noi refliuksnoi bolezni. Meditsinskiy sovet = Medical Council. 2012;(2):56-60 (in Russian).
48. Andreev DN, Kucheriavyi IuA. Perspektivy lecheniia gastroezofageal'noi refliuksnoi bolezni. Consilium Medicum. Gastroenterologiia. 2013;2:9-14 (in Russian).
49. Kucheriavyi IuA, Andreev DN. Perspektivy lecheniia bol'nykh s kislotozavisimymi zabolevaniiami. Klin. perspektivy gastroenterol., gepatol. 2014;2:15-24 (in Russian).
50. Yamashita H, Okada A, Naora K, et al. Adding acotiamide to gastric acid inhibitors is effective for treating refractory symptoms in patients with non-erosive reflux disease. Dig Dis Sci. 2019;64(3):823-31. DOI:10.1007/s10620-018-5377-9
Авторы
И.В. Маев, Д.Н. Андреев*, А.В. Заборовский, Е.Г. Лобанова
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*dna-mit8@mail.ru
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*dna-mit8@mail.ru
________________________________________________
Igor V. Maev, Dmitry N. Andreev*, Andrew V. Zaborovsky, Elena G. Lobanova
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*dna-mit8@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.